脾多肽注射液治疗原发性免疫性血小板减少症的临床疗效观察

Observation About Clinical Efficacy of Lienal Polypeptide Injection for Treating Primary Immune Thrombocytopenia

关键词:  脾多肽注射液  原发性免疫性血小板减少症  临床观察

Key words:  Lienal Polypeptide Injection  primary immune thrombocytopenia  clinical observation

摘要:

目的 探讨脾多肽注射液治疗原发性免疫性血小板减少症的临床疗效。方法 采用随机、对照的方法，将50例患者随机分为对照组和治疗组，对照组采用口服糖皮质激素进行治疗，治疗组采用口服糖皮质激素联合静脉点滴脾多肽注射液进行治疗。观察疗效并进行疗效判定。结果 治疗组有效率为84%，对照组有效率为64%；治疗组血小板开始升高时的起效时间快、达到峰值所需时间短、维持时间长；治疗后2组患者血小板抗体均较治疗前显著降低(P<0.05)，且治疗后治疗组与对照组比较差异有统计学意义(P<0.05)；与治疗前比较，治疗后2组患者网织血小板显著降低(P<0.05)、产板巨核细胞显著升高(P<0.05)，且治疗后治疗组与对照组网织血小板比较差异有统计学意义(P<0.05)；2组治疗后骨髓巨核细胞比较，差异无统计学意义；治疗后2组患者CD3⁺、CD3⁺CD4⁺均较治疗前升高，CD3⁺CD8⁺降低(P<0.05)，治疗后治疗组与对照组比较，T细胞亚群差异均具有统计学意义(P<0.05)。2组患者均无不良反应发生。结论 脾多肽注射液治疗原发性免疫性血小板减少症临床疗效确切，可在临床推广应用。

Abstract:

OBJECTIVE To investigate the clinical efficacy of Lienal Polypeptide Injection treatment of primary immune thrombocytopenia. METHODS 50 patients were randomly divided into the control group and the treatment group. the control group took oral corticosteroids, and the treatment group took oral corticosteroids combined with Lienal Polypeptide Injection. Then observed the effects of two groups and judgment standard for clinical effect. RESULTS The total effective rate was 84% in treatment group and 64% in control group. The blood platelets begin to rise had a rapid onset, time was shortened reaching peak and the effect last longer in treatment group. compared with before treatment, the platelet antibody, reticulated platelet, CD3⁺CD8⁺ of two groups were all decreased significantly(P<0.05), and thromocytogenic megakaryocyte, CD3⁺, CD3⁺CD4⁺ of two groups were all increased significantly after treatment (P<0.05). after treatment, there were remarkable differences between two groups in the index of platelet antibody, reticulated platelet and subset of T cells(P<0.05), while there was no significant differences between two groups in index of bone marrow megakaryocyte. No adverse reactions were observed in both groups. CONCLUSION The Lienal Polypeptide Injection has definite clinical effect in treating primary immune thrombocytopenia, and could be used in the clinical application.